MasTec's Record Backlog Meets a Cash-Flow Reality Check

What happened

MasTec's shares trade near $216 after a 47% one-year rally, but the latest Zacks commentary highlights the uncomfortable gap between record $16.8B backlog and raised 2026 guidance on one hand, and negative free cash flow and weak cash conversion on the other. Filings show Q3 2025 free cash flow was only $20M against $374M adjusted EBITDA, driven by working-capital-intensive growth and rising contract assets, consistent with the news article's concern that growth is being financed on the balance sheet. The DeepValue master report already flagged a crowded, momentum-driven bull case that discounts permitting delays and project-timing risk, while 48-54% of backlog is cancellable master service agreements. At ~51x trailing EPS and ~21x EV/EBITDA with mid-single-digit ROE and margins still below Quanta, the stock embeds near-flawless execution and sustained backlog conversion that quarterly cash flow has not yet demonstrated. Insiders, including the CEO and a director, recently entered large forward sale derivative contracts, adding caution to a setup where analysts and media have overwhelmingly emphasized upside.

Implication

For existing holders, use any strength toward $230 to reduce exposure, as the risk-reward is unfavorable with the stock pricing in flawless execution. New investors should wait for either a pullback toward $175 or evidence over two quarters that revenue and EBITDA beat guidance by at least 5% with positive free cash flow. The key signposts are whether 18-month backlog continues to grow >10% YoY and segment EBITDA margins hold at or above 8% while free cash flow turns reliably positive. A deterioration in book-to-bill below 1.0 or a major project delay on Greenlink would likely compress the multiple further. Conversely, if cash conversion improves and margins approach Quanta's, the thesis could shift, but that has not yet been demonstrated.

Thesis delta

The news article does not alter the thesis but sharpens the focus on free cash flow as the central test. While record backlog and raised guidance support the growth narrative, the repeated inability to convert EBITDA into cash validates the existing 'Potential Sell' rating and crowded sentiment caution. No change to trim-above-$230 or attractive entry at $175; conviction remains moderate.